Back to Journals » Clinical, Cosmetic and Investigational Dermatology » Volume 13

Spotlight on Topical Long-Term Management of Plaque Psoriasis

Authors Carrascosa JM, Theng C, Thaçi D

Received 17 April 2020

Accepted for publication 7 July 2020

Published 29 July 2020 Volume 2020:13 Pages 495—498

DOI https://doi.org/10.2147/CCID.S254114

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Editor who approved publication: Dr Jeffrey Weinberg


Jose Manuel Carrascosa,1 Colin Theng,2 Diamant Thaçi3

1Dermatology Department, Hospital Germans Trías i Pujol, Barcelona, Spain; 2The Skin Specialists & Laser Clinic, Singapore; 3Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany

Correspondence: Jose Manuel Carrascosa
Dermatology Department, Hospital Germans Trías i Pujol, Universitat Autònoma of Barcelona, IGTP Badalona, Barcelona, Espagne
Email jmcarrascosac.germanstrias@gencat.cat

Abstract: During the 28th Congress of the European Academy of Dermatology and Venereology (EADV) held in Madrid in October 2019, an industry hub was dedicated to the long-term management of psoriasis. Psoriasis is a systemic inflammatory disease primarily involving the skin that affects up to 4% of the European population, the majority of whom present with chronic plaque psoriasis. Topical therapies are well established in the first-line treatment of psoriatic plaque flares. Nevertheless, as psoriasis is a chronic disease, long-term control should be considered. The aim of the session was to provide expert opinion on the benefit of long-term maintenance therapy in chronic plaque psoriasis and introduce the concept of pro-active management to decrease the number of relapses and improve patient quality of life. The current guidelines and recommendations were reviewed, as well as the available data on published clinical trials. There is still an important role for topical therapy in psoriasis and current recommendations suggest a maintenance regimen for psoriasis. Adherence optimization and proactive management of relapse can be key factors for obtaining clinical outcomes in topical long-term therapy. Calcipotriol/betamethasone dipropionate foam is the only topical formulation with long-term data as a twice-weekly proactive treatment approach for up to 52 weeks for chronic plaque psoriasis.

Keywords: Cal/BD combination, corticosteroids, adherence, maintenance, relapse

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]